Chapter 68 : Antibacterial Agents*

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Antibacterial Agents*, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch68-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch68-2.gif


Antimicrobial chemotherapy has played a vital role in the treatment of human infectious diseases since the discovery of penicillin in the 1920s. Hundreds of antimicrobial agents have been developed, and multiple agents in a variety of classes are currently available for clinical use. However, the sheer numbers and continuing development of agents make it difficult for clinicians to keep up with progress in the field. Similarly, this variety presents significant challenges for clinical microbiologists, who must decide which agents are appropriate for inclusion in routine and specialized susceptibility testing. This chapter provides an overview of the antibacterial agents currently marketed in the United States, with major emphasis on their mechanisms of action, spectra of activity, important pharmacologic parameters, and toxicities. Antibiotics that have fallen into disuse or remained investigational are mentioned only briefly.

Citation: Lewis, J, Bush K. 2015. Antibacterial Agents*, p 1171-1211. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch68
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of FIGURE 1

Chemical structures of β-lactam antibiotics. doi:10.1128/9781555817381.ch68.f1

Citation: Lewis, J, Bush K. 2015. Antibacterial Agents*, p 1171-1211. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch68
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Waxman DJ,, Strominger JL. 1983. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu Rev Biochem 52: 825869.
2. McDowell TD,, Reed KE. 1989. Mechanism of penicillin killing in the absence of bacterial lysis. Antimicrob Agents Chemother 33: 16801685.
3. Johnson DM,, Stilwell MG,, Fritsche TR,, Jones RN. 2006. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). Diagn Microbiol Infect Dis 56: 6974.
4. Sahm DF,, Brown NP,, Draghi DC,, Evangelista AT,, Yee YC,, Thornsberry C. 2008. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001–2005. Postgrad Med 120: 815.
5. Sahm DF,, Brown NP,, Thornsberry C,, Jones ME. 2008. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 120: 1624.
6. Gerber MA,, Baltimore RS,, Eaton CB,, Gewitz M,, Rowley AH,, Shulman ST,, Taubert KA. 2009. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis. Circulation 119: 15411551.
7. Wilson W,, Taubert KA,, Gewitz M,, Lockhart PB,, Baddour LM,, Levison M,, Bolger A,, Cabell CH,, Takahashi M,, Baltimore RS,, Newburger JW,, Strom BL,, Tani LY,, Gerber M,, Bonow RO,, Pallasch T,, Shulman ST,, Rowley AH,, Burns JC,, Ferrieri P,, Gardner T,, Goff D,, Durack DT. 2007. Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 116: 17361754.
8. Drusano GL,, Schimpff SC,, Hewitt WL. 1984. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis 6: 1332.
9. Bush K,, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54: 969976.
10. Coppens L,, Klastersky J. 1979. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother 15: 396399.
11. Fass RJ,, Copelan EA,, Brandt JT,, Moeschberger ML,, Ashton JJ. 1987. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 155: 12421248.
12. Bartlett JG. 1992. Antibiotic-associated diarrhea. Clin Infect Dis 15: 573581.
13. Bush K,, Heep M,, Macielag MJ,, Noel GJ. 2007. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Invest Drugs 16: 419429.
14. Riccobene TA,, Su SF,, Rank D. 2013. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother 57: 14961504.
15. Schmitt-Hoffmann A,, Roos B,, Schleimer M,, Sauer J,, Man A,, Nashed N,, Brown T,, Perez A,, Weidekamm E,, Kovacs P. 2004. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48: 25702575.
16. Biedenbach DJ,, Jones RN,, Fritsche TR. 2008. Antimicrobial activity of cefditoren tested against contemporary (2004–2006) isolates of Haemophilus influenzae and Moraxella catarrhalis responsible for community-acquired respiratory tract infections in the United States. Diagn Microbiol Infect Dis 61: 240244.
17. Thornsberry C. 1992. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis 14( Suppl 2): S189S194.
18. Vedantam G. 2009. Antimicrobial resistance in Bacteroides spp.: occurrence and dissemination. Future Microbiol 4: 413423.
19. Wexler HM,, Finegold SM. 1988. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 32: 601604.
20. Fass RJ. 1983. Comparative in vitro activities of third-generation cephalosporins. Arch Intern Med 143: 17431745.
21. Neu HC. 1982. The new beta-lactamase-stable cephalosporins. Ann Intern Med 97: 408419.
22. Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend Rep 59( RR-12): 1110.
23. Lindberg R,, Fredlund H,, Nicholas R,, Unemo M. 2007. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 51: 21172122.
24. Medical Letter on Drugs and Therapeutics. 2007. Treatment of Lyme disease. Med Lett Drugs Ther 49: 4951.
25. Jones RN,, Barry AL. 1983. Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis 5( Suppl 1): S108S126.
26. Cohen MA,, Joannides ET,, Roland GE,, Meservey MA,, Huband MD,, Shapiro MA,, Sesnie JC,, Heifetz CL. 1994. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability. Diagn Microbiol Infect Dis 18: 3139.
27. Johnson DM,, Biedenbach DJ,, Beach ML,, Pfaller MA,, Jones RN. 2000. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 37: 99105.
28. Jones RN,, Biedenbach DJ,, Johnson DM. 2000. Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagn Microbiol Infect Dis 37: 143146.
29. Barry AL,, Jones RN. 1987. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates. Pediatr Infect Dis J 6: 954957.
30. Frampton JE,, Brogden RN,, Langtry HD,, Buckley MM. 1992. Cefpodoxime proxetil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 44: 889917.
31. Fung-Tomc JC. 1997. Fourth-generation cephalosporins. Clin Microbiol Newsl 19: 129136.
32. Qadri SM,, Cunha BA,, Ueno Y,, Abumustafa F,, Imambaccus H,, Tullo DD,, Domenico P. 1995. Activity of cefepime against nosocomial blood culture isolates. J Antimicrob Chemother 36: 531536.
33. Carlos J,, Zamorano L,, Pérez JL,, Ge Y,, Oliver A. 2010. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54: 28462851.
34. Brown NP,, Pillar CM,, Sahm DF,, Ge Y. 2009. Activity profile of CXA-101 and CXA-101/tazobactam against target gram-positive and gram-negative pathogens, abstr F1-1986. Abstr 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, CA, 12 to 15 September 2009.
35. McGee L,, Biek D,, Ge Y,, Klugman M,, du Plessis M,, Smith AM,, Beall B,, Whitney CG,, Klugman KP. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 53: 552556.
36. Morrissey I,, Ge Y,, Janes R. 2009. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents 33: 515519.
37. Schirmer PL,, Deresinski SC. 2009. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 7: 777791.
38. Silva N,, Radhouani H,, Goncalves A,, Araújo C,, Rodrigues J,, Igrejas G,, Poeta P. 2010. In vitro activity of ceftobiprole against gram-positive and gram-negative bacteria isolated from humans and animals. J Antimicrob Chemother 65: 801803.
39. Citron DM,, Tyrrell KL,, Merriam CV,, Goldstein EJ. 2010. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 54: 16271632.
40. Kelkar PS,, Li JT. 2001. Cephalosporin allergy. N Engl J Med 345: 804809.
41. Schaad UB,, Wedgwood-Krucko J,, Tschaeppeler H. 1988. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet ii: 14111413.
42. Sattler FR,, Weitekamp MR,, Ballard JO. 1986. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 105: 924931.
43. Lamoth F,, Buclin T,, Pascual A,, Vora S,, Bolay S,, Decosterd LA,, Calandra T,, Marchetti O. 2010. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 54: 43604367.
44. Freifeld AG,, Kent S. 2010. Cefepime and death: reality to the rescue. Clin Infect Dis 51: 390391.
45. Bush K,, Freudenberger JS,, Sykes RB. 1982. Interaction of aztreonam and related monobactams with beta-lactamases from gram-negative bacteria. Antimicrob Agents Chemother 22: 414420.
46. Barry AL,, Thornsberry C,, Jones RN,, Gavan TL. 1985. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis 7( Suppl 4): S594S604.
47. Sykes RB,, Bonner DP. 1985. Aztreonam: the first monobactam. Am J Med 78( Suppl 2A): 210.
48. Buesing MA,, Jorgensen JH. 1984. In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli. Antimicrob Agents Chemother 25: 283285.
49. Saxon A,, Hassner A,, Swabb EA,, Wheeler B,, Adkinson NF, Jr. 1984. Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J Infect Dis 149: 1622.
50. Norrby SF,, Faulkner KL,, Newell PA. 1997. Differentiating meropenem and imipenem/cilastatin. Infect Dis Clin Pract 6: 291303.
51. Spratt BG,, Jobanputra V,, Zimmermann W. 1977. Binding of thienamycin and clavulanic acid to the penicillinbinding proteins of Escherichia coli K-12. Antimicrob Agents Chemother 12: 406409.
52. Chambers HF. 1995. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP2a. Antimicrob Agents Chemother 39: 462466.
53. Mushtaq S,, Ge Y,, Livermore DM. 2004. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 48: 30863092.
54. Craig WA. 1997. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis 24( Suppl 2): S266S275.
55. Nix DE,, Majumdar AK,, DiNubile MJ. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 53( Suppl 2): ii23ii28.
56. Baldwin CM,, Lyseng-Williamson KA,, Keam SJ. 2008. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 68: 803838.
57. Keam SJ. 2008. Doripenem: a review of its use in the treatment of bacterial infections. Drugs 68: 20212057.
58. Poulakou G,, Giamarellou H. 2008. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opin Invest Drugs 17: 749771.
59. Jones RN,, Kirby JT,, Rhomberg PR. 2008. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn Microbiol Infect Dis 61: 203213.
60. Pillar CM,, Torres MK,, Brown NP,, Shah D,, Sahm DF. 2008. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 52: 43884399.
61. Jones RN,, Huynh HK,, Biedenbach DJ. 2004. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 48: 31363140.
62. Denton M,, Kerr KG. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11: 5780.
63. Snydman DR,, Jacobus NV,, McDermott LA. 2008. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group. Antimicrob Agents Chemother 52: 44924496.
64. Snydman DR,, Jacobus NV,, McDermott LA,, Golan Y,, Hecht DW,, Goldstein EJ,, Harrell L,, Jenkins S,, Newton D,, Pierson C,, Rihs JD,, Yu VL,, Venezia R,, Finegold SM,, Rosenblatt JE,, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis 50( Suppl 1): S26S33.
65. Wexler HM,, Engel AE,, Glass D,, Li C. 2005. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 49: 44134417.
66. Edwards JR. 1995. Meropenem: a microbiological overview. J Antimicrob Chemother 36( Suppl A): 117.
67. Goldstein EJ,, Citron DM,, Vreni Merriam C,, Warren Y,, Tyrrell KL. 2000. Comparative in vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 44: 23892394.
68. Neu HC,, Fu KP. 1978. Clavulanic acid, a novel inhibitor of beta-lactamases. Antimicrob Agents Chemother 14: 650655.
69. Bansal MB,, Chuah SK,, Thadepalli H. 1985. In vitro activity and in vivo evaluation of ticarcillin plus clavulanic acid against aerobic and anaerobic bacteria. Am J Med 79: 3338.
70. Finlay J,, Miller L,, Poupard JA. 2003. A review of the antimicrobial activity of clavulanate. J Antimicrob Chemother 52: 1823.
71. Jacoby GA,, Munoz-Price LS. 2005. The new betalactamases. N Engl J Med 352: 380391.
72. Aswapokee N,, Neu HC. 1978. A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot (Tokyo) 31: 12381244.
73. Moosdeen F,, Williams JD,, Yamabe S. 1988. Antibacterial characteristics of YTR830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother 32: 925927.
74. Kuck NA,, Jacobus NV,, Petersen PJ,, Weiss WJ,, Testa RT. 1989. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother 33: 19641969.
75. Jacoby GA,, Sutton L. 1989. Pseudomonas cepacia susceptibility to sulbactam. Antimicrob Agents Chemother 33: 583584.
76. Retsema JA,, English AR,, Girard A,, Lynch JE,, Anderson M,, Brennan L,, Cimochowski C,, Faiella J,, Norcia W,, Sawyer P. 1986. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection. Rev Infect Dis 8( Suppl 5): S528S534.
77. Wexler HM,, Harris B,, Carter WT,, Finegold SM. 1985. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria. Antimicrob Agents Chemother 27: 876878.
78. Appelbaum PC,, Jacobs MR,, Spangler SK,, Yamabe S. 1986. Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes. Antimicrob Agents Chemother 30: 789791.
79. Gutmann L,, Kitzis MD,, Yamabe S,, Acar JF. 1986. Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother 29: 955957.
80. Knapp CC,, Sierra-Madero J,, Washington JA. 1989. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis 12: 511515.
81. Eliopoulos GM,, Klimm K,, Ferraro MJ,, Jacoby GA,, Moellering RC, Jr. 1989. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 12: 481488.
82. Sorgel F,, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J Antimicrob Chemother 31( Suppl A): 3960.
83. Farrell DJ,, Flamm RK,, Sader HS,, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011–2012). Antimicrob Agents Chemother 57: 63056310.
84. Livermore DM,, Mushtaq S,, Warner M,, Miossec C,, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum betalactamases and carbapenemases. J Antimicrob Chemother 62: 10531056.
85. Drawz SM,, Bonomo RA. 2010. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23: 160201.
86. Ehmann DE,, Jahic H,, Ross PL,, Gu RF,, Hu J,, Kern G,, Walkup GK,, Fisher SL. 2012. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A 109: 1166311668.
87. Livermore DM,, Warner M,, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68: 22862290.
88. Hirsch EB,, Ledesma KR,, Chang K,, Schwartz MS,, Motyl MR,, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother 56: 37533757.
89. Ball P. 2000. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46( Suppl 1): 1724.
90. Pucci MJ,, Bush K. 2013. Investigational antimicrobial agents of 2013. Clin Microbiol Rev 26: 792821.
91. Hawkey PM. 2003. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother 51( Suppl 1): 2935.
92. Morgan-Linnell SK,, Becnel Boyd L,, Steffen D,, Zechiedrich L. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53: 235241.
93. Strahilevitz J,, Jacoby GA,, Hooper DC,, Robicsek A. 2009. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22: 664689.
94. Stein GE. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 23( Suppl 1): S19S24.
95. Grasela DM. 2000. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis 31( Suppl 2): S51S58.
96. Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58( Suppl 2): 2936.
97. McCracken GH, Jr. 2000. Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis. Clin Infect Dis 31( Suppl 2): S45S50.
98. Lipman J,, Allworth A,, Wallis SC. 2000. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 31: 11311133.
99. Van der Auwera P,, Matsumoto T,, Husson M. 1988. Intraphagocytic penetration of antibiotics. J Antimicrob Chemother 22: 185192.
100. Anderson VR,, Perry CM. 2008. Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 68: 535565.
101. Dalhoff A,, Schmitz FJ. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 22: 203221.
102. Eliopoulos GM,, Eliopoulos CT,. 1993. Activity in vitro of the quinolones, p 161193. In Hooper DC,, Wolfson JS ( ed), Quinolone Antimicrobial Agents, 2nd ed. American Society for Microbiology, Washington, DC.
103. Lawrence L,, Hopkins S,, Sahm D,, Deane J,, Burak E,, Longcor J. 2012. Characterization and in vitro activity of delafloxacin (DLX) against isolates from a phase 2 study of acute bacterial skin and skin structure infections (ABSSSI), poster E-208. 52nd Intersci Conf Antimicrob Agents Chemother, San Francisco, CA.
104. Adam HJ,, Laing NM,, King CR,, Lulashnyk B,, Hoban DJ,, Zhanel GG. 2009. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53: 49154920.
105. Stubbings W,, Leow P,, Yong GC,, Goh F,, Korber-Irrgang B,, Kresken M,, Endermann R,, Labischinski H. 2011. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 55: 43944397.
106. Lopez Y,, Tato M,, Espinal P,, Garcia-Alonso F,, Gargallo-Viola D,, Canton R,, Vila J. 2013. In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant Gram-positive bacteria. Antimicrob Agents Chemother 57: 63896392.
107. Betriu C,, Rodriguez I-Avial,, Gomez M,, Culebras E,, Picazo JJ. 2005. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997–2002). Diagn Microbiol Infect Dis 53: 221223.
108. Golan Y,, McDermott LA,, Jacobus NV,, Goldstein EJC,, Finegold S,, Harrell LJ,, Hecht DW,, Jenkins SG,, Pierson C,, Venezia R,, Rihs J,, Iannini P,, Gorbach SL,, Snydman DR. 2003. Emergence of fluoroquinolones resistance among Bacteroides species. J Antimicrob Chemother 52: 208213.
109. Snydman DR,, Jacobus NV,, McDermott LA,, Ruthazer R,, Golan Y,, Goldstein EJ,, Finegold SM,, Harrell LJ,, Hecht DW,, Jenkins SG,, Pierson C,, Venezia R,, Yu V,, Rihs J,, Gorbach SL. 2007. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 51: 16491655.
110. Colpan A,, Johnston B,, Porter S,, Clabots C,, Anway R,, Thao L,, Kuskowski MA,, Tchesnokova V,, Sokurenko EV,, Johnson JR, VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 57: 12561265.
111. Sanchez GV,, Master RN,, Karlowsky JA,, Bordon JM. 2012. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 56: 21812183.
112. Centers for Disease Control and Prevention. 2011. National antimicrobial resistance monitoring system: enteric bacteria human isolates final report. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc .gov/NARMS/.
113. Nicodemo AC,, Paez JI. 2007. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Micro Infect Dis 26: 229237.
114. Davies S,, Sparham PD,, Spencer RC. 1987. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. J Antimicrob Chemother 19: 605609.
115. Todd PA,, Faulds D. 1991. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 42: 825876.
116. Young LS,, Berlin OG,, Inderlied CB. 1987. Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med 82( Suppl 4A): 23S26S.
117. Sano C,, Tatano Y,, Shimizu T,, Yamabe S,, Sato K,, Tomioka H. 2011. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents 37: 296301.
118. Kenny GE,, Hooton TM,, Roberts MC,, Cartwright FD,, Hoyt J. 1989. Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother 33: 103107.
119. Raoult D,, Roussellier P,, Galicher V,, Perez R,, Tamalet J. 1986. In vitro susceptibility of Rickettsia conorii to ciprofloxacin as determined by suppressing lethality in chicken embryos and by plaque assay. Antimicrob Agents Chemother 29: 424425.
120. Raoult D,, Torres H,, Drancourt M. 1991. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob Agents Chemother 35: 20702077.
121. Yeaman MR,, Mitscher LA,, Baca OG. 1987. In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob Agents Chemother 31: 10791084.
122. Maurin M,, Gasquet S,, Ducco C,, Raoult D. 1995. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother 39: 23872391.
123. Falagas ME,, Bliziotis IA. 2006. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies. Antimicrob Agents Chemother 50: 2233.
124. Hansen G,, Swanzy S,, Gupta R,, Cookson B,, Limaye AP. 2008. In-vitro activity of fluoroquinolones against clinical isolates of Nocardia identified by partial 16S rRNA sequencing. Eur J Clin Microbiol Infect Dis 27: 115120.
125. Chacon-Moreno BE,, Welsh O,, Cavazos-Rocha N,, de la Luz Salazar-Cavazos M,, Garza-Lozano HG,, Said-Fernandez S,, Ocampo-Candiani J,, Vera-Cabrera L. 2009. Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice. Antimicrob Agents Chemother 53: 295297.
126. Wolfson JS,, Hooper DC. 1989. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2: 378424.
127. Ball P,, Mandell L,, Niki Y,, Tillotson G. 1999. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf 21: 407421.
128. Lipsky BA,, Baker CA. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28: 352364.
129. Stahlmann R,, Lode H. 1999. Toxicity of quinolones. Drugs 58( Suppl 2): 3742.
130. Cohen SH,, Gerding DN,, Johnson S,, Kelly CP,, Loo VG,, McDonald LC,, Pepin J,, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431455.
131. Polk RE. 1989. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 87( Suppl 5A): 76S81S.
132. Arguedas A,, Sher L,, Lopez E,, Saez-Llorens X,, Hamed K,, Skuba K,, Pierce PF. 2003. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J 22: 949956.
133. Arguedas A,, Dagan R,, Pichichero M,, Leibovitz E,, Blumer J,, McNeeley DF,, Melkote R,, Noel GJ. 2006. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 25: 11021109.
134. Medical Letter on Drugs and Therapeutics. 2008. Fluoroquinolones and tendon injuries. Med Lett Drugs Ther 50: 93.
135. Davies JE. 1983. Resistance to aminoglycosides: mechanisms and frequency. Rev Infect Dis 5( Suppl 2): S261S267.
136. Galimand M,, Courvalin P,, Lambert T. 2003. Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation. Antimicrob Agents Chemother 47: 25652571.
137. Shaw KJ,, Rather PN,, Hare RS,, Miller GH. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57: 138163.
138. Bates RD,, Nahata MC. 1994. Once-daily administration of aminoglycosides. Ann Pharmacother 28: 757766.
139. Baddour LM,, Wilson WR,, Bayer AS,, Fowler VG Jr,, Bolger AF,, Levison ME,, Ferrieri P,, Gerber MA,, Tani LY,, Gewitz MH,, Tong DC,, Steckelberg JM,, Baltimore RS,, Shulman ST,, Burns JC,, Falace DA,, Newburger JW,, Pallasch TJ,, Takahashi M,, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111: 394434.
140. Maurin M,, Raoult D. 2001. Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother 45: 29772986.
141. Neu HC. 1976. Tobramycin: an overview. J Infect Dis 134( Suppl): S3S19.
142. Muscato JJ,, Wilbur DW,, Stout JJ,, Fahrlender RA. 1991. An evaluation of the susceptibility patterns of gram-negative organisms isolated in cancer centres with aminoglycoside usage. J Antimicrob Chemother 27( Suppl C): 17.
143. Griffith DE,, Aksamit T,, Brown-Elliott BA,, Catanzaro A,, Daley C,, Gordin F,, Holland SM,, Horsburgh R,, Huitt G,, Iademarco MF,, Iseman M,, Olivier K,, Ruoss S,, von Reyn CF,, Wallace RJ, Jr,, Winthrop K. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367416.
144. Watanakunakorn C,, Tisone JC. 1982. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 22: 903905.
145. Cosgrove SE,, Vigliani GA,, Campion M,, Fowler VG, Jr,, Abrutyn E,, Corey GR,, Levine DP,, Rupp ME,, Chambers HF,, Karchmer AW,, Boucher HW. 2009. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 48: 713721.
146. Fernández-Hidalgo N,, Almirante B,, Gavaldà J,, Gurgui M,, Peña C,, de Alarcón A,, Ruiz J,, Vilacosta I,, Montejo M,, Vallejo N,, López-Medrano F,, Plata A,, López J,, Hidalgo-Tenorio C,, Gálvez J,, Sáez C,, Lomas JM,, Falcone M,, de la Torre J,, Martínez-Lacasa X,, Pahissa A. 2013. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 56: 12611268.
147. Fee WE, Jr. 1980. Aminoglycoside ototoxicity in the human. Laryngoscope 90( Suppl 24): 119.
148. Washington JA, II,, Wilson WR. 1985. Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 60: 189203.
149. Vannuffel P,, Cocito C. 1996. Mechanism of action of streptogramins and macrolides. Drugs 51( Suppl 1): 2030.
150. Lewis JS, II,, Jorgensen JH. 2005. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 40: 280285.
151. Franceschi F,, Kanyo Z,, Sherer EC,, Sutcliffe J. 2004. Macrolide resistance from the ribosome perspective. Curr Drug Targets Infect Disord 4: 177191.
152. Maravic G. 2004. Macrolide resistance based on the erm-mediated rRNA methylation. Curr Drug Targets Infect Disord 4: 193202.
153. Williams JD,, Sefton AM. 1993. Comparison of macrolide antibiotics. J Antimicrob Chemother 31( Suppl C): 1126.
154. Schentag JJ,, Ballow CH. 1991. Tissue-directed pharmacokinetics. Am J Med 91( Suppl 3A): 5S11S.
155. Cherubin CE,, Azabache DB. 1992. While nearly no one was watching: the rise of erythromycin and clindamycin resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Antimicrob Newsl 8: 3744.
156. Barry AL,, Jones RN,, Thornsberry C. 1988. In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob Agents Chemother 32: 752754.
157. Lode H,, Borner K,, Koeppe P,, Schaberg T. 1996. Azithromycin: review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 37( Suppl C): 18.
158. Peters DH,, Friedel HA,, McTavish D. 1992. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44: 750799.
159. Neu HC. 1991. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 27( Suppl A): 19.
160. Blazquez Garrido RM,, Espinosa Parra FJ,, Alemany Frances L,, Ramos Guevara RM,, Sanchez-Nieto JM,, Segovia Hernandez M,, Serrano Martinez JA,, Huerta FH. 2005. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 40: 800806
161. Ouyang-Latimer J,, Jafri S,, VanTassel A,, Jiang ZD,, Gurleen K,, Rodriguez S,, Nandy RK,, Ramamurthy T,, Chatterjee S,, McKenzie R,, Steffen R,, DuPont HL. 2011. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother 55: 874878.
162. Centers for Disease Control and Prevention. 2012. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61: 590594.
163. Stamm WE. 1991. Azithromycin in the treatment of uncomplicated genital chlamydial infections. Am J Med 91( Suppl 3A): 19S22S.
164. Citron DM,, Appleman MD. 2001. Comparative in vitro activities of ABT-773 against 362 clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother 45: 345348.
165. Medical Letter on Drugs and Therapeutics. 2007. Drugs for parasitic infections. Treat Guidel Med Lett 5( Suppl): e1e15.
166. Sullivan D,, Csuka ME,, Blanchard B. 1980. Erythromycin ethylsuccinate hepatotoxicity. JAMA 243: 1074.
167. Baciewicz AM,, Al-Nimir A,, Whelan P. 2005. Azithromycin-induced hepatotoxicity. Am J Med 118: 14381439.
168. Brummett RE,, Fox KE. 1989. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 33: 791796.
169. von Rosensteil NA,, Adam D. 1995. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 13: 105122.
170. Venugopal AA,, Johnson S. 2012. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 54: 568574.
171. Goldstein EJ,, Babakhani F,, Citron DM. 2012. Antimicrobial activities of fidaxomicin. Clin Infect Dis 55( Suppl 2): S143S148.
172. Leeds JA,, Sachdeva M,, Mullin S,, Barnes SW,, Ruzin A. 2014. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 69: 4144.
173. Louie TJ,, Cannon K,, Byrne B,, Emery J,, Ward L,, Eyben M,, Krulicki W. 2012. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 55( Suppl 2): S132S142.
174. Ackermann G,, Rodloff AC. 2003. Drugs of the 21st century: telithromycin (HMV3647)—the first ketolide. J Antimicrob Chemother 51: 497511.
175. Bertrand D,, Bertrand S,, Neveu E,, Fernandes P. 2010. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob Agents Chemother 54: 53995402.
176. Hansen LH,, Mauvais P,, Douthwaite S. 1999. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbiol 31: 623631.
177. Hisanaga T,, Hoban DJ,, Zhanel GG. 2005. Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 56: 447450.
178. Wolter N,, Smith AM,, Farrell DJ,, Schaffner W,, Moore M,, Whitney CG,, Jorgensen JH,, Klugman KP. 2005. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 49: 35543557.
179. Namour F,, Wessels DH,, Pascual MH,, Reynolds D,, Sultan E,, Lenfant B. 2001. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 45: 170175.
180. Farrell DJ,, Felmingham D. 2004. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 48: 18821884.
181. Felmingham D. 2001. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect 7( Suppl 3): 210.
182. Jorgensen JH,, Crawford SA,, McElmeel ML,, Whitney CG. 2004. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 48: 605607.
183. Low DE,, Brown S,, Felmingham D. 2004. Clinical and bacteriological efficacy of the ketolide telithromycin against isolates of key respiratory pathogens: a pooled analysis of phase III studies. Clin Microbiol Infect 10: 2736
184. Drusano G. 2001. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin Microbiol Infect 7( Suppl 3): 2429.
185. Schulin T,, Wennersten CB,, Moellering RC, Jr,, Eliopoulos GM. 1998. In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. J Antimicrob Chemother 42: 297301.
186. Wexler HM,, Molitoris E,, Molitoris D,, Finegold SM. 2001. In vitro activity of telithromycin (HMR 3647) against 502 strains of anaerobic bacteria. J Antimicrob Chemother 47: 467469.
187. Hunfeld KP,, Wichelhaus TA,, Rodel R,, Acker G,, Brade V,, Kraiczy P. 2004. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 48: 344347.
188. Fernandez-Roblas R,, Esteban J,, Cabria F,, Lopez JC,, Jimenez MS,, Soriano F. 2000. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. Antimicrob Agents Chemother 44: 181182.
189. Balfour JA,, Figgitt DP. 2001. Telithromycin. Drugs 61: 815829.
190. Clay KD,, Hanson JS,, Pope SD,, Rissmiller RW,, Purdum PP,, Banks PM. 2006. Severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 144: E1E6.
191. Bearden DT,, Neuhauser MM,, Garey KW. 2001. Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy 21: 12041222.
192. McGehee RF, Jr,, Smith CB,, Wilcox C,, Finland M. 1968. Comparative studies of antibacterial activity in vitro and absorption and excretion of lincomycin and clinimycin. Am J Med Sci 256: 279292.
193. Leclercq R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 34: 482492.
194. Leigh DA. 1981. Antibacterial activity and pharmacokinetics of clindamycin. J Antimicrob Chemother 7( Suppl A): 39.
195. Bartlett JG. 1982. Anti-anaerobic antibacterial agents. Lancet ii: 478481.
196. Iinuma Y,, Baba H,, Mitsuyama J,, Nomura N. 2013. Multicentre survey of the antibiotic susceptibility of anaerobic gram-negative bacilli in Japan, abstr 252. IDWeek, San Francisco, CA.
197. Lee Y,, Park Y,, Kim MS,, Yong D,, Jeong SH,, Lee K,, Chong Y. 2010. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Antimicrob Agents Chemother 54: 39933997.
198. Wybo I,, Van den Bossche D,, Soetens O,, Vekens E,, Vandoorslaer K,, Claeys G,, Glupczynski Y,, Ieven M,, Melin P,, Nonhoff C,, Rodriguez-Villalobos H,, Verhaegen J,, Pierard D. 2014. Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 69: 155161.
199. Aldridge KE,, Ashcraft D,, Cambre K,, Pierson CL,, Jenkins SG,, Rosenblatt JE. 2001. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 45: 12381243.
200. Rose HD,, Rytel MW. 1972. Actinomycosis treated with clindamycin. JAMA 221: 1052.
201. Wittner M,, Rowin KS,, Tanowitz HB,, Hobbs JF,, Saltzman S,, Wenz B,, Hirsch R,, Chisholm E,, Healy GR. 1982. Successful chemotherapy of transfusion babesiosis. Ann Intern Med 96: 601604.
202. Lell B,, Kremsner PG. 2002. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46: 23152320.
203. Dannemann B,, McCutchan JA,, Israelski D,, Antoniskis D,, Leport C,, Luft B,, Nussbaum J,, Clumeck N,, Morlat P,, Chiu J,, Vilde JL,, Haseltine P,, Leedom J,, Remington J,, Orellana M,, Feigal D,, Bartok A,, Heseltine P,, Leedom J,, Remington J. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 116: 3343.
204. Toma E,, Fournier S,, Dumont M,, Bolduc P,, Deschamps H. 1993. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis 17: 178184.
205. Stein GE,, Craig WA. 2006. Tigecycline: a critical analysis. Clin Infect Dis 43: 518524.
206. Chopra I,, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65: 232260.
207. Olson MW,, Ruzin A,, Feyfant E,, Rush TS, III,, O’Connell J,, Bradford PA. 2006. Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 50: 21562166.
208. McAleese F,, Petersen P,, Ruzin A,, Dunman PM,, Murphy E,, Projan SJ,, Bradford PA. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49: 18651871.
209. Peleg AY,, Adams J,, Paterson DL. 2007. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51: 20652069.
210. Ruzin A,, Visalli MA,, Keeney D,, Bradford PA. 2005. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49: 10171022.
211. Pankey GA. 2005. Tigecycline. J Antimicrob Chemother 56: 470480.
212. Moore IF,, Hughes DW,, Wright GD. 2005. Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 44: 1182911835.
213. Agwuh KN,, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256265.
214. Hoeprich PD,, Warshauer DM. 1974. Entry of four tetracyclines into saliva and tears. Antimicrob Agents Chemother 5: 330336.
215. MacGowan AP. 2008. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 62( Suppl 1): i11i16.
216. Meagher AK,, Ambrose PG,, Grasela TH,, Ellis-Grosse EJ. 2005. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41( Suppl 5): S333S340.
217. Rodvold KA,, Gotfried MH,, Cwik M,, Korth-Bradley JM,, Dukart G,, Ellis-Grosse EJ. 2006. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58: 12211229.
218. Sutcliffe JA. 2011. Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241: 122152.
219. Sun H,, Ting L,, Maietta R,, Machineni S,, Praestgaard J,, Kuemmell A,, Stein DS,, Sunkara G,, Kovacs SJ,, Draper MP. 2012. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects, abstr P1423, p 374375. Abstr 22nd Eur Congr Clin Microbiol Infect Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
220. Gupta K,, Hooton TM,, Naber KG,, Wullt B,, Colgan R,, Miller LG,, Moran GJ,, Nicolle LE,, Raz R,, Schaeffer AJ,, Soper DE. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103e120.
221. Johnson JR,, Drawz SM,, Porter S,, Kuskowski MA. 2013. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 57: 48564860.
222. Wallace RJ Jr,, Wiss K. 1981. Susceptibility of Mycobacterium marinum to tetracyclines and aminoglycosides. Antimicrob Agents Chemother 20: 610612.
223. Sack DA,, Sack RB,, Nair GB,, Siddique AK. 2004. Cholera. Lancet 363: 223233.
224. Dewsnup DH,, Wright DN. 1984. In vitro susceptibility of Nocardia asteroides to 25 antimicrobial agents. Antimicrob Agents Chemother 25: 165167.
225. Chung HS,, Hong SG,, Lee Y,, Kim M,, Yong D,, Jeong SH,, Lee K,, Chong Y. 2012. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital. Yonsei Med J 53: 439441.
226. Fishbain J,, Peleg AY. 2010. Treatment of Acinetobacter infections. Clin Infect Dis 51: 7984.
227. Hecht DW. 2004. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 39: 9297.
228. Tubau F,, Linares J,, Rodriguez MD,, Cercenado E,, Aldea MJ,, Gonzalez-Romo F,, Torroba L,, Berdonces P,, Plazas J,, Aguilar L,, Delgado A,, Garcia-Escribano N. 2010. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery. Diagn Microbiol Infect Dis 66: 308313.
229. Fekete T. 1993. Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy. Clin Microbiol Rev 6: 2233.
230. Pang LW,, Limsomwong N,, Boudreau EF,, Singharaj P. 1987. Doxycycline prophylaxis for falciparum malaria. Lancet i: 11611164.
231. Kelesidis T,, Karageorgopoulos DE,, Kelesidis I,, Falagas ME. 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895904.
232. Hoban DJ,, Bouchillon SK,, Dowzicky MJ. 2007. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 57: 423428.
233. Insa R,, Cercenado E,, Goyanes MJ,, Morente A,, Bouza E. 2007. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59: 583585.
234. Goldstein EJ,, Citron DM,, Merriam CV,, Warren YA,, Tyrrell KL,, Fernandez HT. 2006. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 50: 35073513.
235. Wallace RJ, Jr,, Brown-Elliott BA,, Crist CJ,, Mann L,, Wilson RW. 2002. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 46: 31643167.
236. Hope R,, Warner M,, Mushtaq S,, Ward ME,, Parsons T,, Livermore DM. 2005. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 56: 10421046.
237. Ruzin A,, Dzink-Fox J,, Jones AK,, Dean CR,, Bradford PA. 2010. Studies on the mechanism of resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae, abstr C1-1079. Abstr 50th Intersci Conf Antimicrob Agents Chemother.
238. Frost P,, Weinstein GD,, Gomez EC. 1972. Phototoxic potential of minocycline and doxycycline. Arch Dermatol 105: 681683.
239. Walters BN,, Gubbay SS. 1981. Tetracycline and benign intracranial hypertension: report of five cases. Br Med J 282: 1920.
240. Grossman ER,, Walchek A,, Freedman H. 1971. Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics 47: 567570.
241. Zhanel GG,, Homenuik K,, Nichol K,, Noreddin A,, Vercaigne L,, Embil J,, Gin A,, Karlowsky JA,, Hoban DJ. 2004. The glycylcyclines: a comparative review with the tetracyclines. Drugs 64: 6388.
242. Somma S,, Gastaldo L,, Corti A. 1984. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother 26: 917923.
243. Attwood RJ,, LaPlante KL. 2007. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 23352348.
244. Bailey J,, Summers KM. 2008. Dalbavancin: a new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65: 599610.
245. Lin SW,, Carver PL,, DePestel DD. 2006. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 40: 449460.
246. Pace JL,, Yang G. 2006. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 71: 968980.
247. Courvalin P. 2006. Vancomycin resistance in grampositive cocci. Clin Infect Dis 42( Suppl 1): S25S34.
248. Hobbs JK,, Miller K,, O’Neill AJ,, Chopra I. 2008. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62: 10031008.
249. Long JK,, Choueiri TK,, Hall GS,, Avery RK,, Sekeres MA. 2005. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc 80: 12151216.
250. Lewis JS II,, Owens A,, Cadena J,, Sabol K,, Patterson JE,, Jorgensen JH. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49: 16641665.
251. Hayden MK,, Rezai K,, Hayes RA,, Lolans K,, Quinn JP,, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43: 52855287.
252. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44: 655656.
253. Cui L,, Tominaga E,, Neoh H-M,, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50: 10791082.
254. Friedman L,, Alder JD,, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 50: 21372145.
255. Belley A,, McKay GA,, Arhin FF,, Sarmiento I,, Beaulieu S,, Fadhil I,, Parr TR Jr,, Moeck G. 2010. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 54: 53695371.
256. Lunde CS,, Hartouni SR,, Janc JW,, Mammen M,, Humphrey PP,, Benton BM. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 53: 33753383.
257. Fekety R,, Silva J,, Buggy B,, Deery HG. 1984. Treatment of antibiotic-associated colitis with vancomycin. J Antimicrob Chemother 14( Suppl D): 97102.
258. Rybak MJ. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 42( Suppl 1): S35S39.
259. Albanese J,, Leone M,, Bruguerolle B,, Ayem ML,, Lacarelle B,, Martin C. 2000. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 44: 13561358.
260. Moellering RC, Jr, 1984. Pharmacokinetics of vancomycin. J Antimicrob Chemother 14(Suppl D):43–52.
261. Steenbergen JN,, Alder J,, Thorne GM,, Tally FP. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections. J Antimicrob Chemother 55: 283288.
262. Hegde SS,, Reyes N,, Wiens T,, Vanasse N,, Skinner R,, McCullough J,, Kaniga K,, Pace J,, Thomas R,, Shaw JP,, Obedencio G,, Judice JK. 2004. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother 48: 30433050.
263. Saravolatz LD,, Stein GE,, Johnson LB. 2009. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 49: 19081914.
264. Bowker KE,, Noel AR,, MacGowan AP. 2006. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 58: 802805.
265. Bennett JW,, Lewis JS II,, Ellis MW. 2008. Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review. Ther Clin Risk Mgmt 4: 3140.
266. Ambrose PG,, Drusano GL,, Craig WA. 2012. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clin Infect Dis 54( Suppl 3): S220S228.
267. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42( Suppl 1): S13S24.
268. Barry AL,, Fuchs PC,, Brown SD. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 45: 19191922.
269. Wise R,, Andrews JM,, Ashby JP. 2001. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 48: 563567.
270. McKay GA,, Beaulieu S,, Sarmiento I,, Arhin FF,, Parr TR Jr,, Moeck G. 2009. Impact of human serum albumin on oritavancin in vitro activity against enterococci. Antimicrob Agents Chemother 53: 26872689.
271. Mendes RE,, Moet GJ,, Janechek MJ,, Jones RN. 2010. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother 54: 27042706.
272. Cetinkaya Y,, Falk P,, Mayhall CG. 2000. Vancomycin-resistant enterococci. Clin Microbiol Rev 13: 686707.
273. Hiramatsu K. 2001. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1: 147155.
274. Geraci JE,, Wilson WR. 1981. Vancomycin therapy for infective endocarditis. Rev Infect Dis 3( Suppl): S250S258.
275. Morris AB,, Brown RB,, Sands M. 1993. Use of rifampin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 37: 17.
276. Tuazon CU,, Miller H. 1984. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 25: 411412.
277. Rybak MJ. 2006. The efficacy and safety of daptomycin: first in a new class of antibiotics for gram-positive bacteria. Clin Microbiol Infect 12( Suppl 1): 2432.
278. Sader HS,, Jones RN. 2009. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008). Diagn Microbiol Infect Dis 65: 158162.
279. Wootton M,, MacGowan AP,, Walsh TR. 2006. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 50: 41954197.
280. Goldstein EJ,, Citron DM,, Merriam CV,, Warren YA,, Tyrrell KL,, Fernandez HT. 2003. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47: 337341.
281. Tyrrell KL,, Citron DM,, Warren YA,, Fernandez HT,, Merriam CV,, Goldstein EJ. 2006. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother 50: 27282731.
282. Arhin FF,, Draghi DC,, Pillar CM,, Parr TR Jr,, Moeck G,, Sahm DF. 2009. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother 53: 47624771.
283. Billeter M,, Zervos MJ,, Chen AY,, Dalovisio JR,, Kurukularatne C. 2008. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 46: 577583.
284. Kosowska-Shick K,, Clark C,, Pankuch GA,, McGhee P,, Dewasse B,, Beachel L,, Appelbaum PC. 2009. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 53: 42174224.
285. Poulakou G,, Giamarellou H. 2008. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Expert Opin Invest Drugs 17: 225243.
286. Pope SD,, Roecker AM. 2006. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 26: 908918.
287. Saravolatz LD,, Stein GE,, Johnson LB. 2009. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 49: 19081914.
288. Zhanel GG,, Trapp S,, Gin AS,, DeCorby M,, Lagace-Wiens PR,, Rubinstein E,, Hoban DJ,, Karlowsky JA. 2008. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Anti Infect Ther 6: 6781.
289. Nicolau DP,, Sun HK,, Seltzer E,, Buckwalter M,, Dowell JA. 2007. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 60: 681684.
290. Goldstein EJ,, Citron DM,, Tyrrell KL,, Warren YA. 2004. Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile. Anaerobe 48: 21492152.
291. Polk RE,, Healy DP,, Schwartz LB,, Rock DT,, Garson ML,, Roller K. 1988. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 157: 502507.
292. Forouzesh A,, Moise PA,, Sakoulas G. 2009. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 53: 483486.
293. Lodise TP,, Lomaestro B,, Graves J,, Drusano GL. 2008. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52: 13301336.
294. Arbeit RD,, Maki D,, Tally FP,, Campanaro E,, Eisenstein BI, the Daptomycin Investigators, 98–01 and 99–01. 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38: 16731681.
295. Carpenter CF,, Chambers HF. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 38: 9941000.
296. Pechere JC. 1999. Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin. J Antimicrob Chemother 44( Suppl A): 1118.
297. Low DE. 1995. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience. Microb Drug Resist 1: 223234.
298. Bouanchaud DH. 1997. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. J Antimicrob Chemother 39( Suppl A): 1521.
299. Finch RG. 1996. Antibacterial activity of quinupristin/dalfopristin: rationale for clinical use. Drugs 51( Suppl 1): 3137.
300. Lamb HM,, Figgitt DP,, Faulds D. 1999. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 58: 10611097.
301. Linden PK,, Moellering RC Jr,, Wood CA,, Rehm SJ,, Flaherty J,, Bompart F,, Talbot GH. 2001. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 33: 18161823.
302. Moellering RC,, Linden PK,, Reinhardt J,, Blumberg EA,, Bompart F,, Talbot GH, for the Synercid Emergency Use Group. 1999. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 44: 251261.
303. Rubinstein E,, Prokocimer P,, Talbot GH. 1999. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 44( Suppl A): 3746.
304. Olsen KM,, Rebuck JA,, Rupp ME. 2001. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 32: e83e86.
305. Marchese A,, Schito GC. 2001. The oxazolidinones as a new family of antimicrobial agent. Clin Microbiol Infect 7( Suppl 4): 6674.
306. Moellering RC. 2003. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138: 135142.
307. Das B,, Rajarao AV,, Rudra S,, Yadav A,, Ray A,, Pandya M,, Rattan A,, Mehta A. 2009. Synthesis and biological activity of novel oxazolidinones. Bioorg Med Chem Lett 19: 64246428.
308. Gravestock MB. 2005. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Dev 8: 469477.
309. Hoellman DB,, Lin G,, Ednie LM,, Rattan A,, Jacobs MR,, Appelbaum PC. 2003. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone, compared to those of other agents. Antimicrob Agents Chemother 47: 11481150.
310. Swaney SM,, Aoki H,, Ganoza MC,, Shinabarger DL. 1998. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42: 32513255.
311. Bonora MG,, Solbiati M,, Stepan E,, Zorzi A,, Luzzani A,, Catania MR,, Fontana R. 2006. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44: 11531155.
312. Meka VG,, Gold HS. 2004. Antimicrobial resistance to linezolid. Clin Infect Dis 39: 10101015.
313. Campanile F,, Mongelli G,, Bongiorno D,, Adembri C,, Ballardini M,, Falcone M,, Menichetti F,, Repetto A,, Sabia C,, Sartor A,, Scarparo C,, Tascini C,, Venditti M,, Zoppi F,, Stefani S. 2013. Worrisome trend of new multiple mechanisms of linezolid resistance in staphylococcal clones diffused in Italy. J Clin Microbiol 51: 12561259.
314. Stalker DJ,, Jungbluth GL,, Hopkins NK,, Batts DH. 2003. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 51: 12391246.
315. Myrianthefs P,, Markantonis SL,, Vlachos K,, Anagnostaki M,, Boutzouka E,, Panidis D,, Baltopoulos G. 2006. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 50: 39713976.
316. MacGowan AP. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother 51( Suppl S2): ii17ii25.
317. Clemett D,, Markham A. 2000. Linezolid. Drugs 59: 815827.
318. Livermore DM. 2003. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 51( Suppl 2): ii9ii16.
319. Zurenko GE,, Yagi BH,, Schaadt RD,, Allison JW,, Kilburn JO,, Glickman SE,, Hutchinson DK,, Barbachyn MR,, Brickner SJ. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 40: 839845.
320. Brown-Elliott BA,, Crist CJ,, Mann LB,, Wilson RW,, Wallace RJ Jr. 2003. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 47: 17361738.
321. Wallace RJ Jr,, Brown-Elliott BA,, Ward SC,, Crist CJ,, Mann LB,, Wilson RW. 2001. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 45: 764767.
322. Weigelt J,, Itani K,, Stevens D,, Lau W,, Dryden M,, Knirsch C, for the Linezolid CCSTI Study Group. 2005. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49: 22602266.
323. Wunderink RG,, Niederman MS,, Kollef MH,, Shorr AF,, Kunkel MJ,, Baruch A,, McGee WT,, Reisman A,, Chastre J. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54: 621629.
324. Shorr AF,, Kunkel MJ,, Kollef M. 2005. Linezolid versus vancomycin in Staphylococcus aureus bacteremia: pooled analysis of randomized studies. J Antimicrob Chemother 56: 923929.
325. Stevens DL,, Herr D,, Lampiris H,, Hunt JL,, Batts DH,, Hafkin B. 2002. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34: 14811490.
326. Falagas ME,, Siempos II,, Vardakas KZ. 2008. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8: 5366.
327. Perry CM,, Jarvis B. 2001. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 61: 525551.
328. Plouffe JF. 2000. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid. Clin Infect Dis 31( Suppl 4): S144S149.
329. French G. 2003. Safety and tolerability of linezolid. J Antimicrob Chemother 51( Suppl S2): ii45ii53.
330. Rubinstein E,, Isturiz R,, Standiford HC,, Smith LG,, Oliphant TH,, Cammarata S,, Hafkin B,, Le V,, Remington J. 2003. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 47: 18241831.
331. Lee E,, Burger S,, Shah J,, Melton C,, Mullen M,, Warren F,, Press R. 2003. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 37: 13891391.
332. Bressler AM,, Zimmer SM,, Gilmore JL,, Somani J. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 4: 528531.
333. Attassi K,, Hershberger E,, Alam R,, Zervos MJ. 2002. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34: 695698.
334. Gerson SL,, Kaplan SL,, Bruss JB,, Le V,, Arellano FM,, Hafkin B,, Kuter DJ. 2002. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46: 27232726.
335. De Vriese AS,, Coster RV,, Smet J,, Seneca S,, Lovering A,, Van Haute LL,, Vanopdenbosch LJ,, Martin JJ,, Groote CC,, Vandecasteele S,, Boelaert JR. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42: 11111117.
336. Ramsey TD,, Lau TT,, Ensom MH. 2013. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother 47: 543560.
337. Rubin RH,, Swartz MN. 1980. Trimethoprim-sulfamethoxazole. N Engl J Med 303: 426432.
338. Hitchings GH. 1973. Mechanism of action of trimethoprim-sulfamethoxazole. J Infect Dis 128( Suppl): 433436.
339. Patel RB,, Welling PG. 1980. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clin Pharmacokinet 5: 405423.
340. Rodloff AC. 1982. In-vitro susceptibility test of non-tuberculous mycobacteria to sulphamethoxazole, trimethoprim, and combinations of both. J Antimicrob Chemother 9: 195199.
341. Hooton TM,, Stamm WE. 1997. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am 11: 551581.
342. Bushby SR. 1973. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J Infect Dis 128( Suppl): S442S462.
343. Zhanel GG,, Adam HJ,, Baxter MR,, Fuller J,, Nichol KA,, Denisuik AJ,, Lagace-Wiens PR,, Walkty A,, Karlowsky JA,, Schweizer F,, Hoban DJ. 2013. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J Antimicrob Chemother 68( Suppl 1): i7i22.
344. Najjar A,, Murray BE. 1987. Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci. Antimicrob Agents Chemother 31: 808810.
345. Murray BE. 1990. The life and times of the enterococcus. Clin Microbiol Rev 3: 4665.
346. Stapleton A,, Stamm WE. 1997. Prevention of urinary tract infection. Infect Dis Clin North Am 11: 719733.
347. Nadelman RB,, Luger SW,, Frank E,, Wisniewski M,, Collins JJ,, Wormser GP. 1992. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 117: 273280.
348. DuPont HL. 2005. Travelers’ diarrhea: antimicrobial therapy and chemoprevention. Nat Clin Pract Gastroenterol Hepatol 2: 191198.
349. Wallace RJ Jr,, Septimus EJ,, Williams TW Jr,, Conklin RH,, Satterwhite TK,, Bushby MB,, Hollowell DC. 1982. Use of trimethoprim-sulfamethoxazole for treatment of infections due to Nocardia. Rev Infect Dis 4: 315325.
350. Centers for Disease Control and Prevention. 2013. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Centers for Disease Control and Prevention, Atlanta, GA. http://aidsinfo.nih.gov/guidelines/html/5/pediatric-oi-prevention-and-treatment-guidelines/0.
351. Carroll OM,, Bryan PA,, Robinson RJ. 1966. Stevens-Johnson syndrome associated with long-acting sulfonamides. JAMA 195: 691693.
352. Lawson DH,, Paice BJ. 1982. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis 4: 429433.
353. Velazquez H,, Perazella MA,, Wright FS,, Ellison DH. 1993. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119: 296301.
354. Gordin FM,, Simon GL,, Wofsy CB,, Mills J. 1984. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 100: 495499.
355. Landman D,, Georgescu C,, Martin DA,, Quale J. 2008. Polymyxins revisited. Clin Microbiol Rev 21: 449465.
356. Falagas ME,, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40: 13331341.
357. Li J,, Nation RL,, Turnidge JD,, Milne RW,, Coulthard K,, Rayner CR,, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6: 589601.
358. Markantonis SL,, Markou N,, Fousteri M,, Sakellaridis N,, Karatzas S,, Alamanos I,, Dimopoulou E,, Baltopoulos G. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 53: 49074910.
359. Garonzik SM,, Li J,, Thamlikitkul V,, Paterson DL,, Shoham S,, Jacob J,, Silveira FP,, Forrest A,, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55: 32843294.
360. Sandri AM,, Landersdorfer CB,, Jacob J,, Boniatti MM,, Dalarosa MG,, Falci DR,, Behle TF,, Bordinhao RC,, Wang J,, Forrest A,, Nation RL,, Li J,, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57: 524531.
361. Rosenblatt JE,, Stewart PR. 1974. Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli. Antimicrob Agents Chemother 6: 8492.
362. Michalopoulos A,, Papadakis E. 2010. Inhaled anti-infective agents: emphasis on colistin. Infection 38: 8188.
363. Lutsar I,, McCracken GH Jr,, Friedland IR. 1998. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27: 11171127.
364. Neu HC,, Fu KP. 1980. In vitro activity of chloramphenicol and thiamphenicol analogs. Antimicrob Agents Chemother 18: 311316.
365. Shaw WV. 1984. Bacterial resistance to chloramphenicol. Br Med Bull 40: 3641.
366. Smith AL,, Weber A. 1983. Pharmacology of chloramphenicol. Pediatr Clin North Am 30: 209236.
367. Cherubin CE. 1981. Antibiotic resistance of Salmonella in Europe and the United States. Rev Infect Dis 3: 11051126.
368. Edwards DI. 1993. Nitroimidazole drugs—action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31: